重症监护病房620例嗜酸性粒细胞增多症患者的流行病学、临床表现与结局
这项回顾性、全国、多中心(14个中心)队列研究纳入6年内ICU期间两次血标本嗜酸性粒细胞≥1×10⁹/L的成年患者620例(占全部ICU住院0.9%)。40%为早期嗜酸性粒细胞增多(入ICU 24小时内,ICU-Eo1组),56%为延迟型(入ICU 24小时后,ICU-Eo2组)。ICU-Eo1组嗜酸性粒细胞增多多由呼吸系统(14.9%)和血液系统(25.8%)疾病引起,常伴症状(58.1%,主要为呼吸和心血管表现),32.2%需全身糖皮质激素;ICU-Eo2组嗜酸性粒细胞相关器官受累少见(25%),多由药物诱发(46.8%)。入ICU后第60天生存率ICU-Eo1组21.4%、ICU-Eo2组17.2%(p=0.219)。作者认为按嗜酸性粒细胞出现时机可区分两个需不同病因学检查与管理的亚组。
要点
- 纳入标准为从入ICU前一天至ICU最后一天两次血标本嗜酸性粒细胞≥1×10⁹/L的成年患者,620例占全部ICU住院的0.9%。
- 40%为早期嗜酸性粒细胞增多(入ICU 24小时内,ICU-Eo1组),56%为延迟型(入ICU 24小时后,ICU-Eo2组)。
- ICU-Eo1组多由呼吸系统(14.9%)和血液系统(25.8%)疾病引起,58.1%有症状(主要为呼吸和心血管表现),32.2%需全身糖皮质激素。
- ICU-Eo2组嗜酸性粒细胞相关器官受累少见(25%),多由药物诱发(46.8%)。
- 第60天生存率ICU-Eo1组21.4% vs ICU-Eo2组17.2%(p=0.219),两组间未达统计学显著差异。
适用人群与场景
- 成年ICU患者,从入ICU前一天至ICU最后一天两次血标本嗜酸性粒细胞≥1×10⁹/L。
- 按嗜酸性粒细胞出现时机分为早期(入ICU 24小时内,ICU-Eo1组)和延迟型(入ICU 24小时后,ICU-Eo2组)。
诊断标准与关键阈值
- 嗜酸性粒细胞增多定义为两次血标本嗜酸性粒细胞≥1×10⁹/L,采样时间从入ICU前一天至ICU最后一天。
- 早期嗜酸性粒细胞增多:入ICU 24小时内出现(ICU-Eo1组);延迟型:入ICU 24小时后出现(ICU-Eo2组)。
处置流程与药物剂量
- ICU-Eo1组32.2%的病例需全身糖皮质激素治疗。
- 作者认为,根据嗜酸性粒细胞出现时机可区分两个需不同病因学检查与管理的亚组。
红旗征与不能漏的情况
- ICU-Eo1组58.1%有症状,主要为呼吸和心血管表现。
研究设计与关键结果
- 回顾性、全国、多中心(14个中心)队列研究,历时6年,纳入620例患者(占全部ICU住院的0.9%)。
- 早期嗜酸性粒细胞增多(ICU-Eo1组)占40%,延迟型(ICU-Eo2组)占56%。
- ICU-Eo1组嗜酸性粒细胞增多多由呼吸系统(14.9%)和血液系统(25.8%)疾病引起,58.1%有症状(主要为呼吸和心血管表现),32.2%需全身糖皮质激素。
- ICU-Eo2组嗜酸性粒细胞相关器官受累少见(25%),多由药物诱发(46.8%)。
- 入ICU后第60天生存率ICU-Eo1组21.4% vs ICU-Eo2组17.2%(p=0.219)。
- ICU-Eo1组多因素分析中,第60天死亡的危险因素为入ICU时正在使用免疫抑制剂、嗜酸性粒细胞增多源于肿瘤血液系统疾病、入ICU时使用血管升压药。
- ICU-Eo2组中,高龄以及嗜酸性粒细胞增多发生时使用血管升压药或机械通气与更差预后相关。
证据类型、等级与局限
- 证据类型:回顾性、全国、多中心(14个中心)队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,按嗜酸性粒细胞出现时机(入ICU 24小时内 vs 24小时后)可区分两个需不同病因学检查与管理的亚组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Although eosinophil-induced manifestations can be life-threatening, studies focusing on the epidemiology and clinical manifestations of eosinophilia in the intensive care unit (ICU) are lacking.
METHODS: A retrospective, national, multicenter (14 centers) cohort study over 6 years of adult patients who presented with eosinophilia ≥ 1 × 109/L on two blood samples performed from the day before admission to the last day of an ICU stay.
RESULTS: 620 patients (0.9% of all ICU hospitalizations) were included: 40% with early eosinophilia (within the first 24 h of ICU admission, ICU-Eo1 group) and 56% with delayed (> 24 h after ICU admission, ICU-Eo2 group) eosinophilia. In ICU-Eo1, eosinophilia was mostly due to respiratory (14.9%) and hematological (25.8%) conditions, frequently symptomatic (58.1%, mainly respiratory and cardiovascular manifestations) requiring systemic corticosteroids in 32.2% of cases. In ICU-Eo2, eosinophil-related organ involvement was rare (25%), and eosinophilia was mostly drug-induced (46.8%). Survival rates at day 60 (D60) after ICU admission were 21.4% and 17.2% (p = 0.219) in ICU-Eo1 and ICU-Eo2 patients, respectively. For ICU-Eo1 patients, in multivariate analysis, risk factors for death at D60 were current immunosuppressant therapy at ICU admission, eosinophilia of onco-hematological origin and the use of vasopressors at ICU admission, whereas older age and the use of vasopressors or mechanical ventilation at the onset of eosinophilia were associated with a poorer prognosis for ICU-Eo2 patients.
CONCLUSION: Eosinophilia ≥ 1 × 109/L is not uncommon in the ICU. According to the timing of eosinophilia, two subsets of patients requiring different etiological workups and management can be distinguished.
参考来源
- Gaillet A, Bay P, Péju E, et al. Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit. Intensive Care Med. 2023. PMID: 36723637. doi:10.1007/s00134-022-06967-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。